Diamant Thaçi

Learn More
BACKGROUND Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels. The blockade by dupilumab of these key drivers of type 2 helper T-cell (Th2)-mediated inflammation could help in the treatment of related diseases, including atopic dermatitis. (More)
BACKGROUND Interleukin (IL)-17A has major proinflammatory activity in psoriatic lesional skin. OBJECTIVES To assess the efficacy and safety of secukinumab, a fully human IgG1κ monoclonal anti-IL-17A antibody, in moderate-to-severe plaque psoriasis in a phase II regimen-finding study. METHODS A total of 404 patients were randomized to subcutaneous(More)
BACKGROUND Recent observations suggest that psoriasis is a risk factor for the development of coronary artery calcification which in turn represents an indicator for atherosclerosis. OBJECTIVE To clarify a possible pathogenetic link between psoriasis and atherosclerosis, we studied the metabolic state of patients with psoriasis. METHODS Thirty-nine(More)
BACKGROUND Prompt identification and treatment of psoriatic arthritis (PsA) in patients with psoriasis is critical to reducing the risk of joint damage, disability, and comorbidities. OBJECTIVE We sought to estimate PsA prevalence in patients with plaque psoriasis in 34 dermatology centers in 7 European and North American countries. METHODS Consecutive(More)
BACKGROUND Psoriasis is a chronic inflammatory skin disorder affecting about 2% of white-skinned individuals. Epidemiological data on the prevalence and degree of coronary artery calcification (CAC) as an indicator for cardiovascular diseases in patients with psoriasis are contradictory. OBJECTIVES To study the prevalence and degree of CAC as an indicator(More)
BACKGROUND Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has shown superior efficacy to etanercept with similar safety in moderate to severe plaque psoriasis (FIXTURE study). OBJECTIVE We sought to directly compare efficacy and safety of secukinumab versus ustekinumab. METHODS In this 52-week, double-blind study (NCT02074982), 676(More)
BACKGROUND Impaired sleep in patients with moderate-to-severe psoriasis and improvement on therapy has not been widely studied. OBJECTIVE Quantify baseline aspects of sleep and improvement in patients with psoriasis receiving etanercept (ETN) when allowed concomitant topical medications (PRISTINE study). METHODS Patients with moderate-to-severe(More)
Severe psoriasis is associated with significant cardiovascular mortality. We therefore investigated the effects of systemic therapy on the cardiovascular risk of psoriasis patients. Thirteen consecutive patients receiving fumaric acid esters were included and followed for 24 weeks both clinically and by means of laboratory monitoring, 10 completed the(More)
OBJECTIVE Clinical trials in psoriasis and psoriatic arthritis (PsA) involve assessment of the skin and joints. This study aimed to determine whether assessment of the skin and joints in patients with PsA by rheumatologists and dermatologists is reproducible. METHODS Ten rheumatologists and 9 dermatologists from 7 countries met for a combined physical(More)
Marcus Harbord,a,† Vito Annese,b Stephan R. Vavricka,c Matthieu Allez,d Manuel Barreiro-de Acosta,e Kirsten Muri Boberg,f,l Johan Burisch,g Martine De Vos,h Anne-Marie De Vries,i Andrew D. Dick,j Pascal Juillerat,k Tom H. Karlsen,f,l Ioannis Koutroubakis,m Peter L. Lakatos,n Tim Orchard,o Pavol Papay,p Tim Raine,q Max Reinshagen,r Diamant Thaci,s Herbert(More)